koko体育app

Abstract: Objective To study the pharmacokinetics of injected doripenem in Chinese healthy volunteers, in order to optimize dosages for patients. Methods Twelve healthy volunteers were recruited in the three-cross Latin square designed study. Participants received intravenous infusions of 0.25, 0.5 and 1.0 g doripenem sequentially in three periods at a random order. Plasma and urine doripenem were measured by HPLC-UV, using an internal standard method with meropenem for plasma samples and an external standard method for urine samples, respectively. Phoenix?WinNonlin?6.1 pharmacokinetic software was used to calculate non-compartment pharmacokinetics parameters. SPSS 19.0 software was used for statistical analysis. Results A single dose infusion of 0.25, 0.5 and 1.0 g doripenemin 60 min produced the following respective parameters: C^max (11.81±1.52), (22.80±3.80) and (47.26±8.38) μg/mL, T^max (60.42±1.44), (58.33±5.77) and (60.00±0) min, t_1/2 (63.48±10.51), (69.12±16.72) and (69.30±11.71) min, AUC_0-t (1 100.86±150.04), (2 111.50±359.58) and (4 359.50±789.38) μg/(mL·min). Linear Regression and Confidence Interval analyses suggested a linear kinetic characteristic. Doripenem was mainly excreted through kidneys, with 24 h cumulative urine excretion rates ranging from 70% to 75% for the three doses of infusions. It was safe to administer doripenem through infusion in healthy volunteers. Adverse reactions occurred in 19.44%cases of infusions, although all were mild reactions. Tinnitus happened in two cases (8.33%) of infusions, which required close observations. Conclusion Doripenem infusion possesses a linear kinetics. There is no need to adjust the regimenpatients.